Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prednisolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 10/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 9/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 2/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 2/20 | 1.00 |
| ▸ | TNF | P01375 | 1/20 | 1.00 |
| ▸ | IL6 | P05231 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | GLUL | P15104 | 1/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 1/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prednisolone SCHEMBL12396679 | 1.00 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL14420691 | 1.00 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL2737385 | 1.00 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL6566835 | 1.00 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL11413677 | 1.00 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL23863778 | 1.00 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL13044469 | 1.00 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL2597917 | 1.00 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL765329 | 1.00 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL29264693 | 1.00 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768324-B1 | METHODS FOR MODULATING INNATE LYMPHOID CELL ACTIVITY, ANTIBODY DRUG CONJUGATES AND USES IN THERAPY | INST NAT SANTE RECH MED (FR) | 2025-11-26 | — | — | EP | disclosed |
| US-20250228847-A1 | COMBINATION THERAPY FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2025-07-17 | — | — | US | disclosed |
| EP-4504147-A1 | COMBINATION THERAPY FOR TREATING CANCER | Astrazeneca AB (SE) | 2025-02-12 | — | — | EP | disclosed |
| CN-118019750-A | Drug delivery system for local delivery of therapeutic agents and uses thereof | 上海椿安生物医药科技有限公司 | 2024-05-10 | — | — | CN | disclosed |
| WO-2023194525-A1 | COMBINATION THERAPY FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2023-10-12 | — | — | WO | disclosed |
| US-20230218726-A1 | TREATMENT OF VIRAL CONJUNCTIVITIS | OKOGEN, INC. | 2023-07-13 | — | — | US | disclosed |
| CN-115996715-A | Treatment of viral conjunctivitis | 奥可金公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4164639-A1 | TLR7 INHIBITOR IN COMBINATION WITH PREDNISOLONE OR HYDROXYCHLOROQUINE FOR TREATING CUTANEOUS LUPUS ERYTHEMATOSUS | Bristol-Myers Squibb Company (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-4138882-A1 | TREATMENT OF VIRAL CONJUNCTIVITIS | Okogen, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| CN-115701995-A | Combination of a TLR7 inhibitor and prednisolone or hydroxychloroquine for the treatment of cutaneous lupus erythematosus | 百时美施贵宝公司 | 2023-02-14 | — | — | CN | disclosed |
| US-20090082314-A1 | Targeting Prodrugs for the Treatment of Gastrointestinal Diseases | THE PROVOST FELLOWS AND SCHOLARS OF THE COLLEGE OF THE | 2009-03-26 | — | — | US | disclosed |
| US-20090082314-A1 | Targeting Prodrugs for the Treatment of Gastrointestinal Diseases | THE PROVOST FELLOWS AND SCHOLARS OF THE COLLEGE OF THE | 2009-03-26 | — | — | US | disclosed |
| US-20090047234-A1 | Compositions for nasal delivery | YISSUM, RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2009-02-19 | — | — | US | disclosed |
| WO-2009003970-A1 | TARGETING DIAZO PRODRUGS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2009-01-08 | — | — | WO | disclosed |
| US-20070142335-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070142335-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070105933-A1 | Amino alcohol compounds | SANKYO COMPANY, LIMITED (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105933-A1 | Amino alcohol compounds | SANKYO COMPANY, LIMITED (JP) | 2007-05-10 | — | — | US | disclosed |
| US-7199150-B2 | Amino alcohol compounds | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| US-7199150-B2 | Amino alcohol compounds | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082314-A1 | Targeting Prodrugs for the Treatment of Gastrointestinal Diseases | SI, NFKBIA, RELA | NR3C1 163/4885HIF1A 2604/4885HSD17B10 1626/4885 |
| US-20250228847-A1 | COMBINATION THERAPY FOR TREATING CANCER | AR, KLK3, KLK5 | NR3C1 1218/4885HIF1A 1502/4885HSD17B10 409/4885 |
| US-20070105933-A1 | Amino alcohol compounds | ADH1C, C9, SSB | NR3C1 116/4885HIF1A 1275/4885HSD17B10 852/4885 |
| US-20070142335-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | HRH3, C3AR1, HRH4 | NR3C1 65/4885HIF1A 1862/4885HSD17B10 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.